ACHE and early-onset autosomal dominant Alzheimer disease: Several AChE inhibitors named as “cognitive enhancers “are being investigated for the symptomatic treatment of Alzheimer’s disease but few have been approved by the Food and Drug Administration in the United States [2,8,10,11].